---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040929"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:20:34.596599+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated

## Summary
- Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.
- Revenue $35K from Roche collaboration, down from $152K year-over-year.
- R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.
- Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).
- FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'.

## SEC filing metadata
- accession: 0000950170-23-040929
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/0000950170-23-040929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/sybx-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040929
- JSON: https://secwatch.observer/filing/0000950170-23-040929.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040929.txt

## Key facts
- Earnings Releases
  SYNLOGIC, INC. reported the quarter ended June 30, 2023 results: revenue $35 thousand, net income consolidated net loss of $15.0 million, or $0.21 per share.
  - Period: the quarter ended June 30, 2023
  - Revenue: $35 thousand
  - Net income: consolidated net loss of $15.0 million, or $0.21 per share
  - Result: reported results
  source text: 2023 Financial Results and Financial Outlook As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/0000950170-23-040929-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.